Citius Oncology, Inc. (CTOR): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$5.49M

Year ended 2025-09-30

2022-12-31 Operating Cash Flow (USD) 2025-09-30

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-09-30	-$5.49M	n/m	2025-12-23, From 2024-10-01
2024-09-30	$126.4K	n/a	2025-12-23, From 2023-10-01
No annual figure between 2022-12-31 and 2024-09-30.
2022-12-31	-$48.0K	n/a	2024-04-16, From 2022-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Citius Oncology, Inc. (CTOR)	2025-09-30	-$5.49M	n/m
iBio, Inc. (IBIO)	2026-06-30	-$23.22M	n/m
Minerva Neurosciences, Inc. (NERV)	2025-12-31	-$13.51M	n/m
Tenax Therapeutics, Inc. (TENX)	2025-12-31	-$35.80M	n/m
Immix Biopharma, Inc. (IMMX)	2025-12-31	-$23.93M	n/m
Aytu Biopharma, Inc (AYTU)	2026-06-30	$3.28M	n/m
Celularity Inc (CELU)	2025-12-31	-$13.25M	n/m
Arbutus Biopharma Corp (ABUS)	2025-12-31	-$39.64M	n/m
Journey Medical Corp (DERM)	2025-12-31	-$12.44M	n/m

Compare CTOR, IBIO, NERV, TENX side by side · Screen every company in Pharmaceutical Preparations ↗